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Wilms’ tumor, or nephroblastoma, is the most common
pediatric renal cancer. The tumors morphologically re-
semble embryonic kidneys with a disrupted architecture
and are associated with undifferentiated metanephric
precursors. Here, we discuss genetic and epigenetic find-
ings in Wilms’ tumor in the context of renal development.
Many of the genes implicated in Wilms’ tumorigenesis
are involved in the control of nephron progenitors or the
microRNA (miRNA) processing pathway. Whereas the
first group of genes has been extensively studied in normal
development, the second finding suggests important roles
for miRNAs in general—and specific miRNAs in particu-
lar—in normal kidney development that still await fur-
ther analysis. The recent identification of Wilms’ tumor
cancer stem cells could provide a framework to integrate
these pathways and translate them into new or improved
therapeutic interventions.
Wilms’ tumors and kidney development
Wilms’ tumors, or nephroblastomas, are pediatric cancers
that develop in young children, usually before the age of
5 years. Despite being relatively rare in absolute numbers
(they affect one in 10,000 children), they are extensively
studied for a variety of reasons. First, although treatment
outcome has improved over recent decades, there re-
mains a strong clinical need to improve therapies to both
minimize secondary effects later in life due to current
treatments and find more effective therapies for high-risk
histological subtypes and relapsed patients (Perotti et al.
2013). Second, it was one of the three types of cancer on
which Knudson (Knudson and Strong 1972) based his two-
hit model for tumor suppressor genes, and the loss of
Wilms’ tumor 1 (WT1) in a subset of Wilms’ tumor cases
remains an archetypal example of a classic tumor suppres-
sor gene, as originally proposed. Since then, many varia-
tions in classifications and the genetics and mechanics of
tumor suppressor genes have been found (Berger et al.
2011), and the biological basis of the multiple tumors that
arise in genetically predisposed individuals may clearly
involve genes other than WT1. Third, Wilms’ tumors are
the direct result of maldevelopment of the embryonic
kidney, an important experimental model that has been
studied for over six decades and has led to many funda-
mental insights that were afterward applied to other
systems. As such, Wilms’ tumors are a model to study
the link between normal development and tumorigenesis.
Understanding normal kidney development will help
our understanding and treatment of Wilms’ tumors, and
understanding Wilms’ tumors genetically and mechanis-
tically will help the understanding of normal kidney
development. In this review, we focus on this last aspect
and provide an update on the many recent developments
in the Wilms’ tumor field.
Wilms’ tumors recapitulate normal nephrogenic differ-
entiation, but whereas normal developing nephrons are
beautifully structured, nephrogenic structures in Wilms’
tumors are disorganized (Fig. 1). The metanephric kidney
develops from the intermediate mesoderm (IM). This
structure gives rise to three cell types and structures that
will form the kidney: the epithelial nephric or Wolffian
duct, Six2-positive mesenchymal cells that will form the
nephrons, and Foxd1-positive cells that will give rise to
the stromal cells (Costantini and Kopan 2010; Li et al.
2014b). Kidney development starts when an epithelial
outgrowth of the Wolffian duct forms and invades the IM
(Fig. 2). This invasion process will set off bidirectional
communication between the epithelial cells, by now
called the ureteric bud, and the mesenchymal cells, now
called the metanephric mesenchyme. This leads to the
first bifurcation of the ureteric bud and the condensation of
the mesenchymal cells to form the cap mesenchyme
around the tips of the ureteric bud. The cells that form
the cap mesenchyme are marked by Six2 and are the
nephron progenitor cells. Lineage tracing has shown that
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the complete nephron is derived from these cells (Kobayashi
et al. 2008), and loss of Six2 leads to a rapid exhaustion of
these progenitors and ectopic epithelization (Self et al.
2006). Responding to signals from the bud and stroma,
these progenitor cells will form a pretubular aggregate
and undergo a mesenchymal-to-epithelial transition
(MET) to form the renal vesicle. This structure will fuse
with its distal end to the ureteric bud to form a continuous
open connection to the ureteric bud. Via the comma-
shaped and S-shaped body stages, it will form the tubule
that, as differentiation progresses, gets patterned into the
proximal tubule, loop of Henle, and distal tubule that
make up the nephron. Each of these parts will express
specific transporters to allow the proper function of the
nephron. Moreover, from early in the patterning process,
podocyte precursors can be found at the most proximal
end of the nephron. Together with invading endothelial
and mesangial cells and the cells that make up Bowman’s
capsule, they will eventually form the glomerulus, in
which the mature podocytes perform the actual filtering
functions of the nephron (Schell et al. 2014). As this
nephrogenic program is executed, the ureteric bud will
keep on growing and branching. Each time new bud tips
are formed, the induction process is repeated, and new
nephrons start to form, connect to the bud, and pattern to
form a functional nephron. In the final, mature nephron,
the blood will enter through the capillaries and is filtered
by the podocytes, and valuable electrolytes, water,
sugars, and other molecules are transported back into
the blood. The remainder is drained into the ureteric bud,
which by then has formed the collecting duct system, and
goes to the bladder for disposal. In humans, metanephric
kidney development starts around week 5 of gestation
and continues until week 36, whereas in mice, the
ureteric bud invades the metanephric mesenchyme at
embryonic day 10.5 (E10.5), and initiation of new neph-
Figure 1. Wilms’ tumors resemble fetal kidneys. (A) Human
fetal kidney (18-wk gestation) showing blastema (metanephric
mesenchyme), epithelial differentiation (S-shaped body), stroma,
and a mature glomerulus. (B) A triphasic Wilms’ tumor showing
all three cell types: blastema, epithelia, and stroma. (Bl) Blastema;
(SSB) S-shaped body; (St) stroma; (Gl) glomerulus; (IES) immature
epithelial structure.
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Figure 2. Schematic representation of kidney development. The ureteric bud (gray) extends from the Wolffian duct, and, upon contact
with the metanephric mesenchyme (red), reciprocal signaling induces both bud bifurcation and condensation of the mesenchyme to
generate the cap mesenchyme. The blastemal mesenchyme then undergo a MET to generate the renal vesicle, which continues to form
the comma-shaped and S-shaped body before the distal end fuses with the ureteric bud (which forms the collecting duct), and the
proximal end joins to form the glomerulus, generating the mature nephron (dark orange).
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rons continues until day 3 after birth. The repetitive
nature of branching and nephron induction will yield
;13,000 nephrons in a mouse kidney and 1 million in
a human kidney, and the centrifugal branching pattern
will also lead to a tissue architecture with older nephrons
on the inside and younger nephrons on the outside of the
renal cortex.
From early on, it has been clear that Wilms’ tumor
development is tightly linked to this developmental pro-
cess. Wilms’ tumors are found associated with so-called
nephrogenic rests, of which there are two types. Intra-
lobar nephrogenic rests (ILNRs) are located toward the
renal medulla and are thought to arise early in renal
development, whereas perilobar nephrogenic rests (PLNRs)
are located toward the periphery of the kidney, the region
that retains nephrogenic activity until late in gestation.
These nephrogenic rests are histologically recognizable
structures that resemble embryonic developmental stages
normally not found in the postnatal kidney (Beckwith et al.
1990), suggesting that a block in the nephrogenic process is
an early, maybe even initiating, step in the formation of
Wilms’ tumors. This was further emphasized by genome-
wide expression analysis ofWilms’ tumor xenografts (Dekel
et al. 2006) and recently inmore detail by the study of Gadd
et al. (2012), which described an expression analysis of
a larger set of Wilms’ tumors that not only identified five
subsets of tumors based on expression patterns but could
also couple this to different stages at which nephron
development was blocked. It is therefore not surprising that
many genes foundmutated inWilms’ tumors have essential
roles in nephron development.
Wilms’ tumor genetics
Overall, there are very few genes commonly mutated in
Wilms’ tumor, and all show relatively low mutation fre-
quencies. The discovery of many Wilms’ tumor-associated
genes began with studying constitutional syndromes that
confer predisposition. For many years, Wilms’ tumors have
been recognized as occurring at a highly elevated rate in
patients withWAGR (Wilms’ tumor, aniridia, genitourinary
anomalies, and mental retardation) syndrome, Beckwith-
Wiedemann syndrome (BWS), hemihypertrophy, Denys-
Drash, and Perlman syndrome. However, these were not
associated with genomic aberration until much later, when
methods for detecting chromosomal aberrations improved.
Constitutional chr11p13 deletions were initially found in
patients with Aniridia-associated Wilms’ tumor (Francke
et al. 1979) and then later identified in sporadic nonsyn-
drome-associated cases (Kaneko et al. 1981; Slater and de
Kraker 1982). In 1990, the candidate gene at 11p13, WT1,
was finally characterized (Call et al. 1990; Gessler et al.
1990) and shown to be a zinc finger DNA-binding trans-
cription factor involved in genitourinary development
(Pritchard-Jones et al. 1990). Germline mutations in WT1
are associated with WAGR (Grundy et al. 1995) and Denys-
Drash (Pelletier et al. 1991) syndromes and are more often
seen in tumors with a stromal subtype (Schumacher et al.
1997). A somatic inactivating mutation or deletion ofWT1
is found in ;12% of Wilms’ tumors and is considered an
‘‘early’’ event, as mutations are also seen in associated
ILNRs (Park et al. 1993; Fukuzawa et al. 2007).
The next Wilms’ tumor gene identified, also with a role
in renal development, was CTNNB1, which is mutated
somatically in 15% of tumors, often alongside a WT1
mutation (Koesters et al. 1999; Maiti et al. 2000).CTNNB1
encodes b-catenin, a key protein involved in the Wnt
signaling pathway, which is critical for epithelialization
after MET (Koesters et al. 1999). In Wilms’ tumor, the
CTNNB1 mutation commonly occurs at a specific acti-
vating residue (Ser45) (Kusafuka et al. 2002), causing
nuclear accumulation of b-catenin (Koesters et al. 2003).
CTNNB1mutations have been defined as a ‘‘late’’ event in
Wilms’ tumorigenesis, as they have been observed in
Wilms’ tumors but not nephrogenic rests (Fukuzawa
et al. 2007; Grill et al. 2011). Other potential mechanisms
for increased Wnt signaling in Wilms’ tumor have been
identified, including overexpression of humanDickkopf-1,
a Wnt signaling antagonist (Wirths et al. 2003), as well as
loss ofWT1, which negatively regulates Wnt signaling via
transcriptional activation of WID (WT1-induced inhibitor
of Dishevelled) (Kim et al. 2010).
WTX (Wilms’ tumor on chromosome X, also known as
AMER1) further links both the WT1 and CTNNB1 genes
together, as the protein negatively regulates Wnt signal-
ing (Major et al. 2007) and has been associated withWT1
transcriptional control (Rivera et al. 2009). WTX is
inactivated by mutation or deletion in ;18% of tumors
(Rivera et al. 2007; Ruteshouser et al. 2008) and has been
described as a tumor suppressor gene. WTX mutations
have been observed in both tumor and nephrogenic rest
tissue; however, its role in tumor initiation has been
disputed as an initiating event due to the heterogeneity
of the mutation within a tumor (Wegert et al. 2009;
Fukuzawa et al. 2010), the fact that germline WTX
mutations do not predispose to Wilms’ tumor (Jenkins
et al. 2009), and a lack of linkage between polymorphic
SNPs atWTX and Wilms’ tumor compared with controls
(Guertl et al. 2010). Some reports coupleWTX function to
the genes directly involved in the control of nephron
progenitors (which is discussed in more detail below). It
was shown to modulate Wt1 activity (Rivera et al. 2009)
and negatively regulates b-catenin being part of the
degradation complex (Major et al. 2007). Wtx knockout
mice are perinatal lethal with phenotypes in multiple
tissues of mesodermal origin (Moisan et al. 2011), con-
sistent with the germline mutations found in sclerosing
skeletal dysplasia (Jenkins et al. 2009). The kidney
phenotype in these mice is confusing, being either agen-
esis or overgrowth, often in the same animal. These data
therefore cannot confirm a causative role in Wilms’
tumor development, although multiple roles and pheno-
types during kidney development—reminiscent of the
multiple Wt1 phenotypes—remains a possibility. Addi-
tional conditional analyses are required to shed light on
this possibility.
Besides genes already known to be central players in
renal development, mutations in other cancer-associated
genes have been identified, including TP53 (Lemoine
et al. 1992). TP53mutation or loss of copy number occurs
Wilms’ tumors and kidney development
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in a low proportion of Wilms’ tumor (;5%) but is
particularly associated with tumors that show anaplasia.
These tumors show characteristic copy number profiles
with multiple focal areas of gain or loss that are generally
absent in tumors with wild-type TP53, showing that TP53
loss is associatedwith genomic instability; these cases often
have a poor prognosis (Bardeesy et al. 1994;Maschietto et al.
2014).WTXmutation may play a role in TP53 inactivation,
as in vitro evidence suggests that WTX modulates CBP/
p300-mediated TP53 acetylation and hence expression
(Kim et al. 2012). It has become clear that p53 is functional
in the development ofmultiple tissues; although, in general,
Tp53-deficient mice are viable, on certain genetic back-
grounds, increased embryonic mortality is found (El-Dahr
et al. 2014). On a C57BL/6 background, multiple congenital
abnormalities in the kidneys can be found (Saifudeen et al.
2009), but none of these have an obvious link to Wilms’
tumor development. However, it should be noted that the
mutations found inWilms’ tumors aremissense rather than
loss-of-function alleles. Mouse models with missense al-
leles are available (Frese and Tuveson 2007), and appropriate
in vivo modeling with these might determine whether the
role of p53 in Wilms’ tumors reflects a developmental role
for TP53 in the developing kidney after all or amore general
role in overseeing genomic stability in proliferating cells in
general and control of the response to any problems that
occur as cells divide.
High expression and copy number gain of MYCN have
been associated withWilms’ tumor for a long time (Nisen
et al. 1986; Norris et al. 1988; Williams et al. 2010), and,
recently, mutations in MYCN were identified by exome
sequencing (Rakheja et al. 2014), including a recurrent
mutation (P44L) previously identified in neuroblastoma
and believed to be a gain-of-function mutation (Williams
et al. 2015). MYCN is a target of ubiquitination and
degradation by FBXW7, which is deleted or mutated in
;4% of tumors (Williams et al. 2010). Together, this
evidence suggests the combined role of different genetic
events leading toMYCN overexpression inWilms’ tumor
and supports studies that describe elevated expression of
MYCN in tumors with (Norris et al. 1988) and without
(Nisen et al. 1986) gene amplification.
The most recent evidence highlighting novel Wilms’
tumor genes was generated by exome sequencing in
which mutations in microRNA (miRNA) processor genes
DICER1, DROSHA, XPO5, DGCR8, and TARBP2 were
identified (Torrezan et al. 2014). The effect of mutation in
miRNA processor genes in Wilms’ tumor is discussed
later. These genome-wide mutation analyses also identi-
fied low-frequency somatic mutations in epigenetic
remodelers SMARCA4 and ARID1A (Rakheja et al.
2014). Very recently, mutations inDROSHA andDGCR8
were also identified in exome sequencing studies of high-
risk blastemal Wilms’ tumors (Wegert et al. 2015) and
favorable histology Wilms’ tumors (Walz et al. 2015).
These studies also identified a recurring Q177R missense
mutation in both SIX1 and SIX2.
CTR9 was only recently identified as a Wilms’ tumor
predisposition gene in families (Hanks et al. 2014). It is
part of the PAF1c complex, which associates with the
RNA polymerase II (Pol II) complex (Jaehning 2010). It is
important in embryonic stem cells (ESCs) to maintain
their pluripotent state (Ding et al. 2009), but specific
kidney functions or even its expression pattern have not
been described. Again, it remains to be seen whether the
mutations found in Wilms’ tumor families reflect a spe-
cific kidney development function or a general require-
ment for the PAF1c complex in many processes and cell
types, including the developing kidney.
Wilms’ tumor epigenetics
From early on, it was realized that, on a chromosomal
scale, pediatric cancers, including Wilms’ tumor, had
relatively stable genomes (Cox 1966), and this has been
confirmed by the low mutation frequencies reported.
Around the same time that WT1 was characterized,
interest in a second region on 11p, the 11p15.5 locus,
showed that BWSwas associatedwith IGF2 overexpression
and that tumors commonly lose the maternal allele,
resulting in homozygosity (Scott et al. 1985; Schroeder
et al. 1987; Koufos et al. 1989). These phenomena were not
associated until later, when genomic imprinting was
identified (Wilkins 1988; Ogawa et al. 1993): where one
allele is expressed in a parent of origin-dependent manner
that is controlled by DNA methylation.
At 11p15.5, an H19 imprinting control region (ICR) is
located that controls expression of IGF2 and H19 and is
differentially methylated depending on the chromosome
parent of origin. Maternal alleles are methylated, pre-
venting CTCF binding and IGF2 expression; however,
H19 is actively expressed. Conversely, the paternal chro-
mosome is not methylated, allowing CTCF binding,
which blocks H19 expression and allows IGF2 expres-
sion. In BWS and Wilms’ tumor, loss of the maternal
allele and duplication of the paternal allele by either loss
of heterozygosity (LOH) or aberrant gain of methylation
at the H19-ICR results in biallelic IGF2 expression
(Ogawa et al. 1993). LOH has been detected outside of
tumor tissue, in the normal kidney and blood cells of
BWS patients (Schneid et al. 1991), which provided the
first evidence that IGF2 overexpression does not neces-
sarily result in Wilms’ tumorigenesis. Furthermore, mo-
saic loss of imprinting (LOI) was seen in the surrounding
kidney and nephrogenic rests (Ohlsson et al. 1999).
Transgenic overexpression of the genomic mouse Igf2
locus in mouse ESCs followed by the production of
chimeric mice resulted in BWS-like phenotypes, such as
overgrowth fetuses with overgrown kidneys, but no renal
abnormalities that support a causative role in Wilms’
tumors (Sun et al. 1997). The same was found in a knock-
out study of H19, where only maternal inherited alleles
were affected, and overgrowth was observed in the off-
spring (Leighton et al. 1995; Ripoche et al. 1997). Other
data based on ‘‘imprint-free’’ ESCs have also argued against
the oncogenic potential of IGF2 LOI on its own (Holm
et al. 2005). However, the same lack of Wilms’ tumors is
seen in theWt1 knockout mouse unless additional muta-
tions are introduced, even though it is clearly a bone fide
Wilms’ tumor gene. A recent mouse model has provided
Hohenstein et al.
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strong evidence for a driver role in Wilms’ tumor of the
combination ofWt1mutation and Igf2 overexpression (Hu
et al. 2011). WhileWT1mutation is often associated with
maternal 11p allele loss that spans the IGF2 locus, this
combination accounts for only ;5%–20% of somatic
mutations in human Wilms’ tumor, and additional events
must accompany IGF2 expression changes to driveWilms’
tumor in the majority of cases with LOH/LOI at this locus
that lack WT1mutation.
Many other site-specific and global epigenetic events
have been described in Wilms’ tumor that may be
associated with development of the tumor, including
promoter methylation-associated gene silencing, meth-
ylation aberration at imprinted loci, long-range epige-
netic silencing, and satellite DNA hypomethylation.
These include genes known to be involved in tumorigen-
esis as well as development, growth, and Wnt signaling
(see Table 1); however, very few epigenetic abnormalities
(other than IGF2/H19) have the full range of experimental
evidence to substantiate mechanistic involvement. Still,
the available evidence seems to suggest a close relation-
ship between the epigenetic controls of normal kidney
development and epigenetic aberrations in Wilms’
tumorigenesis (Charlton et al. 2015).
There are several lines of evidence suggesting that the
WT1 gene can directly influence the epigenome; for
example, WT1 transcriptionally regulates an enzyme that
sets de novo DNA methylation marks, DNMT3A, by
binding the DNMT3A promoter (Szemes et al. 2013).
This interaction thereby influences the methylation
status and reciprocal gene expression levels of many
target genes. This was demonstrated by overexpression
ofWT1 in human embryonic kidney cells that resulted in
acquired DNA methylation at specific gene promoters
where DNMT3A recruitment was increased and resulted
in gene silencing. Depletion ofWT1 inWilms’ tumor cells
led to reactivation of gene expression from methylated
promoters. WT1 has also been shown to affect chromatin
structures around the Wnt4 gene during renal develop-
ment (see below) and specifically binds and recruits
Polycomb complex proteins SUZ12 and EZH2 as well
as another DNA methylation regulator, DNMT1, to
repress Pax2 expression (Xu et al. 2011). Given this
evidence, it is possible that in Wilms’ tumors with WT1
mutation, the loss of normal WT1 activity leads to loss of
tight epigenetic regulation, giving cells increased epige-
netic plasticity and therefore growth advantage. Wilms’
tumor animal models might help to elucidate the mech-
anism by whichWT1mutation or deletion leads to global
or site-specific epigenetic alterations.
Besides DNA methylation, chromatin modification
also alters gene expression. ChIP-seq (chromatin immu-
noprecipitation [ChIP] combined with deep sequencing)
has been performed on three Wilms’ tumors as well as
embryonic kidney and normal kidney tissues using anti-
bodies against H3K4me3 (marking transcriptional initia-
Table 1. Epigenetic aberrations associated with Wilms’ tumor
Epigenetic aberration Loci involved Significance References
Promoter methylation CASP8, CDH1, CRBP1,
and CTCF-binding site
downstream from WT1,
DAPK, GLIPR1/RTVP-1,
HACE1, HIN-1, MGMT,
NORE1A, P14ARF,
P16INK4A, RASSF1A,
and SLIT2
Each of these genes has been
shown to have aberrant
gain or loss of methylation
that is associated with
change in gene expression,
although no functional
relationship was shown.
Several of these genes are
implicated in
tumorigenesis. This
evidence suggests an
alternative mechanism
other than genetic
mutation that alters gene
expression.
Harada et al. 2002; Wagner et al.
2002; Morris et al. 2003;
Anglesio et al. 2004;
Shigematsu et al. 2005;
Chilukamarri et al. 2007;
Haruta et al. 2008; Ohshima
et al. 2012; Zitzmann et al.
2014
Imprinted genes: loss of
imprinting
NNAT, KCNQ1DN,
IGF2AS, IGF2, MEST,
DLK1, RTL1, MEG3,
and reciprocal changes
in expression
Imprinted genes key for
development and growth
that show mechanistic
evidence for a relationship
between aberrant
methylation and gene
expression in Wilms’ tumor.
Hubertus et al. 2011, 2013;
Okutsu et al. 2000; Xin et al.
2000
Long-range hypermethylation 5q31 Silencing of the
protocadherin cluster by
methylation results in
disruption of Wnt signaling
in Wilms’ tumor.
Dallosso et al. 2009
Evidence of satellite/repetitive DNA
showing aberrant methylation
Demonstrative of loss of
global epigenomic
regulation.
Ehrlich et al. 2003; Nishiyama
et al. 2005; Ludgate et al. 2013
Wilms’ tumors and kidney development
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tion when present at promoters), H3K36me3 (marking
active genes), and H3K27me3 (marking silent promoters)
and comparedwith data fromESCs (Aiden et al. 2010). The
results of this study supported previous evidence that
Wilms’ tumors are governed by a set of transcription
factors essential for normal renal development and con-
firmed SIX2 as a key master transcription factor. Further-
more, by studying H3K4me3 at gene promoters, a set of
genes enriched for epigenetic regulators that were posi-
tively expressed in ESCs and Wilms’ tumor but not
expressed in normal kidneys was identified. This evidence
suggests that Wilms’ tumors maintain the activity of key
epigenetic remodelers, allowing them to adapt to their
microenvironment to overcome growth inhibition (as
discussed in Timp and Feinberg 2013). Indeed, reacquisi-
tion of epigenetic plasticity gives cancer cells self-renewal
and proliferation capacity, similar to normal progenitor
populations.
The same study further described the presence of ‘‘bi-
valent domains’’ (combined H3K4me3 and H3K27me3
chromatin) inWilms’ tumors, which identified a subset of
genes expressed in normal kidney but with low expres-
sion in the tumors. In ESCs, bivalent domains mark
developmental loci that are considered essential for normal
development and are resolved during cellular differentia-
tion by losing either chromatin mark, thereby causing the
underlying gene to become either expressed or repressed.
Unsurprisingly, a subset of the genes that aberrantly
retained their bivalent chromatin structure in Wilms’
tumor is strongly expressed in mouse kidney epithelial
structures, indicating that Wilms’ tumor cells are pre-
vented from expressing key epithelial genes and therefore
differentiating properly. As other domains that are bivalent
in ESCs showed H3K27me3 and no expression in Wilms’
tumors, Aiden et al. (2010) suggested that Wilms’ tumors
show partial lineage commitment. They concluded that
developmental arrest occurs in undifferentiated metaneph-
ric mesenchyme, as genes required for differentiation
(FOXD1 and LHX1, which are involved in stromal and
epithelial differentiation, respectively) are among the sub-
set of genes with bivalent chromatin that is not expressed.
As polycomb proteins are involved in establishing
H3K27me3, another (earlier) study examined levels of
polycomb proteins (EZH2, BMI-1, EED, and SUZ12) in
embryonic kidneys, adult kidneys, and Wilms’ tumors
(Metsuyanim et al. 2008). Of these polycomb genes, only
EZH2 was developmentally regulated during renal devel-
opment, whereas in progressive Wilms’ tumor xenografts,
EZH2, EED, SUZ12, and BMI-1 were all up-regulated
compared with pooled mid-gestation embryonic kidneys,
suggesting an increase in activity in the tumor tissue.
These data give important insights into the biology of
Wilms’ tumor cells, which, due to their developmentally
disrupted state, maintain an undifferentiated epigenome.
If the maintained bivalent domains could be manipulated
to resolve, expression of these underlying genesmay force
differentiation and result in a less malignant phenotype.
This hypothesis requires testing, but resetting epigenetic
states in other cancers has already been proven successful
(Stricker et al. 2013).
Wilms’ tumors and the control of nephron progenitor
cells
WT1 is expressed throughout kidney development and
has essential functions at multiple stages during nephro-
genesis (for review, see Ozdemir and Hohenstein 2014). In
the IM, it has a prosurvival role, as, in the conventional
knockoutmouse, massive apoptosis of these cells leads to
renal agenesis (Kreidberg et al. 1993). In the cap mesen-
chyme, Wt1 is essential for the MET (Davies et al. 2004),
the developmental stage believed to be disrupted in the
development of Wilms’ tumors (Huff 2011). This step has
long been known to be controlled by Wnt4, which is
essential (Stark et al. 1994) and sufficient (Kispert et al.
1998) for nephron induction. Wt1 has now been shown to
directly controlWnt4 expression in a dichotomous man-
ner at the chromatin level using a ‘‘chromatin flip-flop.’’
Via this mechanism, Wt1 controls histone modifications
of the complete Wnt4 locus, as delineated by CTCF
insulator elements, in a cell type-dependent and two-
directional manner (Essafi et al. 2011), thereby providing
a rationale for the inactivating mutations in Wilms’
tumors through control of the nephron progenitor cell
population. In the cap mesenchyme, Wt1 keeps theWnt4
locus in an open/active state characterized by H3K4me3
histonemodifications, while in the epicardium,Wt1 keeps
the locus in a repressed/inactive state with H3K27me3
modifications. Loss of Wt1 results in the Wnt4 locus
getting repressed and its expression being lost in the
kidney mesenchyme, while the opposite was found in
the epicardium. The molecular details via which Wt1
controls these histone modifications remain unclear, but
the flip-flop mechanism could explain how Wt1 can exert
its different functions in different stages of the developing
nephron (Ozdemir and Hohenstein 2014). Wt1 is essential
in later stages of nephrogenesis, as shown using heterozy-
gous mutants, additional conditional models, and specific
missense and splicing mutants (Hammes et al. 2001; Guo
et al. 2002; Menke et al. 2003; Gao et al. 2004; Chau et al.
2011; Gebeshuber et al. 2013). These data illustrate the
role of Wt1 mutations in glomerular sclerosis rather than
Wilms’ tumors (Miller-Hodges and Hohenstein 2012) and
emphasize the importance of developmental stage-specific
disruption of nephron development (Gadd et al. 2012), as
too early or too late loss of Wt1 will not lead to tumor
formation. WT1 mutant Wilms’ tumors are usually stro-
mal predominant (Miyagawa et al. 1998; Schumacher et al.
2003), and this is likely linked to the separation of the
mesenchymal renal lineage in Foxd1+ stromal cells and
Six2+ nephron progenitor cells early in renal development
and the apparent earlier stage of origin of WT1 mutant
tumors as described by Gadd et al. (2012).
The strong correlation between WT1 loss and activat-
ing CTNNB1mutations in tumors strongly suggests that
any role for b-catenin in control of theMETwill be tightly
linked to the role ofCTNNB1 andWT1 inWilms’ tumors.
Indeed, b-catenin is a key regulator of the choice of
nephron progenitor cells to remain in their stem cell state
or be induced, go through the MET, and form an epithe-
lialized nephron. The ureteric bud-derived signal that
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induces the nephron formation is mediated byWnt9b that
acts on the Six2-positive nephron progenitor cells in the
cap mesenchyme. In these cells, it signals via the canon-
ical, b-catenin-mediated Wnt pathway to control expres-
sion of Six2 andWnt4 (Karner et al. 2011; Park et al. 2012).
This genetic network is further controlled by a Yap/Taz-
mediated signal downstream from Fat4 in the stromal cells
(Das et al. 2013). Fat4 expressed on the surface of stromal
cells will activate the Hippo pathway in the outer layer of
the cap mesenchyme. This will result in phosphorylation
of Yap and Taz in these cells, keeping these proteins
cytoplasmic and inactive. In the absence of nuclear Yap/
Taz, b-catenin signaling downstream from Wnt9b will
activate target genes involved in nephron induction and
differentiation. The inner layer of the cap mesenchyme
receives the same Wnt9b signal as the outer layer, but
since there is no direct contact with the stroma, the Hippo
pathway will not get activated, and Yap/Taz will not be
phosphorylated, translocate to the nucleus, and shift the
b-catenin response from differentiation target genes to
progenitor self-renewal targets (Das et al. 2013). Interest-
ingly, Fat4-deficient kidneys show a developmental block
that resembles nephrogenic rests, and the cytoplasmic
retention of phosphorylated YAP is disturbed specifically
in anaplastic Wilms’ tumors (Murphy et al. 2014).
MYCN is coexpressed with WT1 in the developing
kidney, and WT1 has been shown to mediate MYCN
expression, at least in vitro, causing overexpression of
MYCN when the WT1 DNA-binding domain is mutated
(Zhang et al. 1999; Udtha et al. 2003). The gene is
expressed at high levels in the nephron progenitor cells
(Mugrauer et al. 1988). Mycn-deficient embryos die at
E10.5–E12.5, with a reduction in the number of meso-
nephric tubules (Charron et al. 1992). When analyzed in
organ culture, Mycn mutant metanephroi and kidneys
with reduced Mycn levels using a hypomorphic allele
were smaller due to reduced proliferation but could un-
dergo the normal MET (Bates et al. 2000). Xu et al. (2014)
have now shown that Eya1 functions genetically up-
stream of Six2 and that the two proteins directly bind
theMycn protein. This leads to dephosphorylation of T58
of Mycn (using the phosphatase activity of Eya1). Phos-
phorylation of this residue leads to degradation of the
protein and exit from the cell cycle. It is conceivable that
uncontrolled activation of MYCN through increased
expression, increased copy number, or gain-of-function
alleles like the recurrent P44L mutation can lead to
increased proliferation of the nephron progenitors and
thereby favor the self-renewal and stemness of these cells
(Laurenti et al. 2009).
The recent identification of Q177R missense muta-
tions in SIX1 and SIX2 (Walz et al. 2015; Wegert et al.
2015) fit neatly with a central role for disturbed control of
nephron progenitors in Wilms’ tumors. The mutations
are somatic, and the majority was found to be in a het-
erozygous state, in which case wild-type and mutant
alleles showed equal expression. All of this points to
a dominant effect of these mutations that, at least for
SIX2, is fully consistent with the observed phenotypes.
Whereas loss of Six2 in mice leads to ectopic epithelial-
ization and rapid exhaustion of the nephron progenitors
(Self et al. 2006), these dominant mutations are giving the
opposite effect, as they are found in blastemal-type
Wilms’ tumors (Walz et al. 2015; Wegert et al. 2015).
Six1 acts upstream of Six2, and loss of Six1 in mice leads
to an earlier phenotype than loss of Six2; the metanephric
mesenchyme is formed but reduced in size, and conden-
sates are not formed (Xu et al. 2003). Since Six1 and Eya1
work together in a transcriptional complex (Xu 2013), we
hypothesize that the mutations found in SIX1 and SIX2
feed back to the control of MYCN, further supported by
the fact that the unsupervised clustering of the blastemal
tumors placed the SIX1/2mutant samples in a group that
is characterized by up-regulation of cell cycle genes. The
exact molecular effect of the Q177R mutation in both
genes remains unclear, but genome-wide ChIP data for
SIX1-Q177R suggested a shift in DNA-binding specificity
and corresponding gene expression changes rather than
loss of DNA binding (Wegert et al. 2015).
Combined, the data above provide a mechanistic ratio-
nale for disturbed control of nephron progenitor cells in
the origin of Wilms’ tumors (Fig. 3). Careful modeling of
Wilms’ tumor-associated mutations in animal models
could explain the occurrence and combinations of these
mutations in these tumors and provide a unique insight
into the earliest events in a tumorigenic process. The data
also suggest that other genes involved in the nephron
progenitor control process will be strong candidate genes
for Wilms’ tumorigenesis.
Wilms’ tumor cancer stem cells
Disturbance of the control of nephron progenitor cells as
an early event in Wilms’ tumor development has direct
implications for the cancer stem cell model. This model
describes how a small subset of cells with stem cell
properties in a tumor gives rise to the bulk of the tumor.
As these stem cell properties make these stem cell-like
cells insensitive to DNA damage-inducing agents, cur-
rent therapies often fail to hit this essential target
population and can even enrich for these cancer stem
cells, making relapse more likely. The cancer stem cell is
closely linked but not necessarily identical to the cell of
origin of the tumor (Visvader 2011). A variety of genetic
and epigenetic studies had identified a strong stemness
phenotype inWilms’ tumors (for review, see Pode-Shakked
and Dekel 2011), but, for a long time, the putative Wilms’
tumor cancer stem cell remained unknown. It took
optimization of xenograft procedures for Wilms’ tumors
to identify an NCAM1+/ALDH1+ population that showed
all characteristics of a Wilms’ tumor cancer stem cell
(Pode-Shakked et al. 2013). Transplantation of just 200
double-positive cells in immune-compromised mice is
sufficient to induce tumors that recapitulate the triphasic
nature of the original tumor, and specific targeting of this
cell population with anti-NCAM1 antibodies conjugated
with a cytotoxic drug effectively stopped the growth of
tumors in the Wilms’ tumor xenograft model.
At present, it is not yet clear how these NCAM1+/
ALDH1+ cells relate to the nephron progenitor population.
Wilms’ tumors and kidney development
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In human embryonic kidneys, where cell isolation
methods are currently limited to cell surface markers,
NCAM1-positive cells have been identified as nephron
progenitor cells with potential stem cell therapeutic
potential (Harari-Steinberg et al. 2013). NCAM1 is ex-
pressed in the Six2-positive nephron progenitors but also
in the first few epithelialized stages, and it is not clear
which NCAM1 subpopulation is responsible for the pro-
genitor phenotype. Even more confusing is the ALDH1+
phenotype of the cells. ALDH1 status is usually deter-
mined using an enzymatic activity assay (ALDEFLUOR)
instead of an expression analysis. There are three human
ALDH1 paralogs (four inmice), each with its own cell type-
specific expression pattern in the developing kidney, and it
is not clear which of these is responsible for the ALDH1
activity in Wilms’ tumor (and other) cancer stem cells.
Surprisingly, recent data suggest that the NCAM1+/
ALDH1+ cancer stem cells dedifferentiate to a more
mesenchymal state from which the bulk of the tumor
forms (Shukrun et al. 2014). This clearly has consequences
for the interpretation of the identity of the Wilms’ tumor
cancer stem cells in the context of the normal nephron
progenitor cells. It also emphasizes potential limitations of
deducing the developmental stage of origin of different
subgroups of tumors from expression patterns and histol-
ogy. As different subgroups of Wilms’ tumors could have
a different developmental stage of origin (Gadd et al. 2012),
it is possible that the different groups have different cancer
stem cells. However, despite these limitations, at least for
the moment, the identification of NCAM1+/ALDH1+ can-
cer stem cells in at least some Wilms’ tumors will provide
new insights in the developmental origins of the tumors.
The miRNA pathway in Wilms’ tumorigenesis
Multiple lines of evidence support the significance of the
miRNA processing pathway in Wilms’ tumorigenesis.
This pathway (shown in Fig. 4) generatesmaturemiRNAs
that negatively regulate protein expression by targeting
mRNAs. Recent excitement surrounding the disruption
of the miRNA processing pathway in Wilms’ tumor arose
after identification of inactivating DIS3L2 mutations in
the Wilms’ tumor susceptibility disease Perlman syn-
drome (Astuti et al. 2012). DIS3L2 is involved in recog-
nition and degradation of polyuridylated mRNA and
miRNAs (Chang et al. 2013). Specific targets of DIS3L2
include uridylated pre-let-7 miRNAs, and this process of
uridylation is performed by LIN28-activated TUT4
and TUT7 enzymes (see Fig. 4; Heo et al. 2009; Thornton
et al. 2012; Chang et al. 2013). By binding to the Let-7 pre-
miRNA loop, LIN28 blocks DICER processing and
therefore expression of mature let-7 miRNAs in un-
differentiated cells during development, maintaining cell
renewal and pluripotency. Let-7 miRNAs are considered
to have tumor suppressor activity, and therefore, not
surprisingly, overexpression of LIN28 is oncogenic. Indeed,
a mouse model with kidney-specific Lin28 overexpression
generated Wilms’ tumor-like lesions, further discussed
below. Of note, LIN28 can also bind to pri-Let-7 miRNA
in the nucleus, preventing DROSHA/DGCR8 processing;
however, the mechanism of degradation of LIN28-bound
pri-Let-7 in this instance is unknown. Therefore, common
hits to the same Let-7 biogenesis pathway (LIN28 over-
expression or inactivation of DIS3L2) result in aberrant
mature Let-7 miRNA expression and are associated with
Wilms’ tumor.
Other miRNAs have been specifically associated with
Wilms’ tumor, including miRNAs that can predict che-
moresponsiveness in blastemal Wilms’ tumors (Watson
et al. 2013). For example, miR-192, miR-215, and miR-
194 all showed significantly lower expression in Wilms’
tumors compared with normal kidneys, whereas other
miRNAs show cell type-specific up-regualtion or down-
regulation (Senanayake et al. 2012). Several of these
miRNAs were shown to target the activin receptor
type 2B (ACVR2B, expressed in the cap mesenchyme)
(Metsuyanim et al. 2009), a member of the TGF-b path-
way, and loss of their expression inWilms’ tumors resulted
in up-regulation of the receptor, suggesting that the TGF-b
pathway may be important in tumorigenesis. Expression
Figure 3. Control of nephron progenitor cells is
disturbed in many Wilms’ tumors. Model for the
control of the fate of nephron progenitor cells.
Eya1 lies genetically upstream of Six2. Six2
labels the nephron progenitor cells, which can
either maintain a progenitor state and self-renew
or differentiate via the Wnt4-mediated MET.
Wnt4 expression is under the direct control of
Wt1. b-Catenin is involved in both progenitor
cell fates through activation of different tran-
scriptional programs. Active nuclear phosphory-
lated Yap/Taz shifts the progenitor balance
toward the self-renewal fate. Eya1 and Six2 in-
teract directly with Mycn, leading to dephos-
phorylation of Mycn pT58, stabilization of the
protein, increased proliferation, and potentially a shift of the nephron progenitor toward self-renewal. Genes activated in Wilms’
tumors are depicted in green, and inactivated genes are in blue. Deregulation of Yap/Taz in Wilms’ tumors results in phosphorylated
Yap not being retained in the cytoplasm as it should, but it translocates to the nucleus and thus shifts the progenitor cell balance toward
self-renewal. This model is likely a simplification, as it presumes that all Wilms’ tumors, regardless of causative mutation, are caused
by the same mechanism.
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of both transcription factor E2F3 and Oncomir-1 (an
oncogenic cluster of miRNAs on chr13 regulated by
E2F3) was increased in Wilms’ tumor compared with
normal tissue, with the increase correlating with high
stage and metastatic disease (Kort et al. 2008). This in-
dicates the role of specific miRNAs in tumor progression.
The final piece of evidence, as briefly mentioned above,
was the frequent number of mutations found in several
miRNA processor genes in Wilms’ tumor, including
DROSHA, DICER1, DGCR8, XPO5, and TARBP2 (see
Fig, 4; Torrezan et al. 2014). Overall, 33% of Wilms’
tumors (22 out of 66) examined had mutations or de-
letions in miRNA processor genes, and these often
occurred in combination, resulting in multiple hits to
the same pathway in one tumor, with XPO5 and TARBP2
mutations frequently occurring together (Torrezan et al.
2014). The most commonly mutated miRNA processor
gene isDROSHA, in 12% ofWilms’ tumors (26 out of 222),
most frequently occurring as a heterozygous E1147K
mutation altering a Mg2+-binding residue of the RNase IIIb
domain. Although one study found mutually exclusive
mutations in WT1/CTNNB1 and miRNA processors
(Rakheja et al. 2014), another found that in four out of 10
tumors with DROSHAmutation,WT1mutation was also
seen (Torrezan et al. 2014).
Germline DICER1 mutations were first found in pa-
tients with renal tumors in 2010, but DICER1mutations
were not identified in the germline of any of 50 patients
with sporadicWilms’ tumors (Bahubeshi et al. 2010). This
shows that although DICER1 mutations were later asso-
ciated with Wilms’ (Foulkes et al. 2011; Slade et al. 2011),
they are not fully penetrant. This may be associated with
the fact that more than one hit is required for tumori-
genesis—either biallelic DICER1 mutation (Wu et al.
2013) or a hit to another miRNA processor.
Dicer has been shown to be important for maintaining
the viability of self-renewing progenitors in renal de-
velopment, demonstrated by the premature termination
of nephron formation with Six2-Cre-mediated removal of
Dicer activity (Nagalakshmi et al. 2011). This evidence
appears contrary to the findings inWilms’ tumor indicating
thatmutation of DICER1 is associated with tumorigenesis.
Furthermore, whereas common mutations in the DICER1
RIIIb domain showed that 5pmiRNAs are mainly affected,
DROSHA and DGCR8 mutations result in failure to
generate mature miRNAs in general (Torrezan et al.
2014). So how does dysregulation of a protein involved in
such a general process lead to tumorigenesis?
The answer is unclear butmay again be associated with
the developmental nature of Wilms’ tumor. It can be
hypothesized that if the miRNA processor mutation was
to occur somatically within a renal progenitor cell, the
cell stage-specific array of pre-miRNAs expressed would
fail to be correctly processed, resulting in loss of mature
miRNAs required for gene silencing. Several studies have
identified miRNAs that are down-regulated in Wilms’
tumor and impact on expression of key genes involved in
renal development. For example, miR-23a shows low
expression in Wilms’, and, as miR-23a regulates HOXB4,
the decrease in the tumor was associated with HOXB4
overexpression (Koller et al. 2013). HOXB4 was shown in
developing chicks to mediate expression of kidney-spe-
cific genes in the nonkidney intermediate mesenchyme
(Preger-BenNoon et al. 2009); therefore, a decrease inmiR-
23a may result in reactivation of HOXB4 and kidney-
specific genes, resulting in persistent embryonic renal
Figure 4. The miRNA processing pathway is com-
monly mutated in Wilms’ tumor. Expression of mature
miRNA is initiated by RNA polymerase-mediated tran-
scription of DNA-encoded sequences into pri-miRNA,
which form a long double-stranded hairpin. This struc-
ture is then cleaved by a complex of Drosha and
DGCR8 (termed Pasha) into a smaller pre-miRNA
hairpin, which is exported from the nucleus and then
cleaved by Dicer (an RNase) and TRBP (with specificity
for dsRNA) to remove the hairpin loop and leave two
single-stranded miRNAs. The functional strand binds to
Argonaute (Ago2) proteins into the RNA-induced si-
lencing complex (RISC), where it guides the complex to
its target mRNA, while the nonfunctional strand is
degraded. Targeting of mRNAs by this method results
in mRNA silencing by mRNA cleavage, translational
repression, or deadenylation. Let-7 miRNAs are a family
of miRNAs highly expressed in ESCs with tumor
suppressor properties. In cases in which LIN28 is over-
expressed, LIN28 binds to pre-Let-7 miRNA, preventing
DICER from binding and resulting in LIN28-activated
polyuridylation by TUT4 or TUT7, causing reciprocal
DIS3L2-mediated degradation of Let-7 pre-miRNAs.
Genes involved in miRNA processing that have been
associated with Wilms’ tumor are highlighted in blue
(inactivating) and green (activating) and include DRO-
SHA, DGCR8, XPO5 (encoding exportin-5), DICER1,
TARBP2, DIS3L2, and LIN28.
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tissue. Similar findings in several other studies showed
that down-regulation of miR-562, miR-204, and miR-185
correlated with increased expression of EYA1 (Drake et al.
2009), MEIS1, and SIX1 (Imam et al. 2010), respectively. In
particular, miR-185 was shown to inhibit anchorage-in-
dependent growth and cell migration in addition to sup-
pressing tumor growth in vivo, implicating it as a potent
tumor suppressor silenced in Wilms’ tumor (Imam et al.
2010). Therefore, by failing to generate mature miRNAs,
the normal nephrogenic differentiation process cannot
continue, as primordial renal genes cannot be silenced,
and cells remain stuck in a precursor-like state. Germline
mutations in miRNA processor genes very rarely lead to
Wilms’ tumor; therefore, it is more likely that timing is
key to the resulting phenotype.
Wilms’ tumor animal models
Animal models for cancer are an essential tool to un-
derstand the genetic, molecular, and cellular events that
lead to cancer initiation and progression and for the
development and testing of therapeutic intervention. In
particular, for studying the developmental aspects of
Wilms’ tumor, they are indispensable. Animal models
can be either xenograft models of human tumors in
immune-compromised mice or genetically modified an-
imals. As this review focuses on the developmental
aspects of Wilms’ tumors, we limit the description of
animal models to the latter group.
The first Wilms’ tumor gene,WT1, was cloned in 1990,
and this was rapidly (for those days) followed by the
description of a Wt1-deficient mouse model (Kreidberg
et al. 1993). Its embryonic-lethal phenotype at mid-
gestation showed the importance of the gene in many
different developing tissues. However, mutant embryos
showed complete renal agenesis due to massive apoptosis
of the IM. Not only did this severely limit the usefulness
of this model for Wilms’ tumor development, an apopto-
tic phenotype was completely counterintuitive to the
loss of a tumor suppressor gene. OtherWt1mousemodels
were generated that showed a pivotal role of Wt1 in other
stages of nephron development and analyzed the role of
specific isoforms (for review, see Ozdemir andHohenstein
2014), but it was not until a breakthrough in 2011 that the
first Wt1 mutant mouse tumor model was described (Hu
et al. 2011). This model combined two genetic events
found in Wilms’ tumor patients—loss of Wt1 (in mice
through a conditional allele) and activation of Igf2 (inmice
through loss ofH19)—andwas the first clear evidence that
the same genes that cause Wilms’ tumors in patients can
do so in mice as well.
Whereas theWt1mouse models were directly based on
mutations found in patients, the Lin28 tumor model took
the opposite route. Almost serendipitously, it was found
that a Vasa-Cre mouse used to drive Lin28a overexpres-
sion in primordial germ cells led, through leaky expres-
sion in the kidney, to the development of Wilms’ tumors
(Urbach et al. 2014). Use of kidney-specific Cre lines
confirmed the finding, making Lin28 a genuine Wilms’
tumor gene candidate through overexpression. A sub-
sequent analysis of human Wilms’ tumor samples iden-
tified LIN28B overexpression in 18 out of 105 tumors as
well as in the NCAM1+/ALDH1+ cancer stem cells
(Urbach et al. 2014), making this another patient-relevant
Wilms’ tumor mouse model.
The patient relevance of two other mouse models is less
clear at present. One study used a conditionally activated
b-catenin model with a conditionally activated Kras allele
in combination with kidney-specific Cre lines and found
metastatic tumors that resembled the epithelial component
of Wilms’ tumors (Clark et al. 2011). A potential problem
with this model is that there are no reports of KRAS
mutations in Wilms’ tumors, making the genetic back-
ground of this model difficult to interpret. This is not to say
that the model does not have any value; it is very well
possible that the pathways that are affected in these mice
are the same as deregulated pathways in human tumors, but
further study of this is required.
Finally, it was shown recently that interrupted in vivo
induced pluripotent stem cell (iPSC) reprogramming of
renal tubular cells resulted in tumors that resembled
Wilms’ tumors (Ohnishi et al. 2014). Surprisingly, con-
tinued reprogramming of tumor cells resulted in normal
iPSCs that could contribute to normal kidney structures
in chimeric mice, something that would not be expected
from cells with mutations that cause Wilms’ tumors. The
background of this model makes it difficult to consider
this as a model for tumors in patients, but it does
highlight the importance of ‘‘stemness’’ in general for
Wilms’ tumors and could provide valuable information
on the mechanics of Wilms’ tumor development in this
way. It also highlights the importance of experienced
histopathological analysis of models; the step from
blocked development to Wilms’ tumor is subtle, and care
should be taken with proper interpretation.
The apparent difficulties in generating mouse models
for Wilms’ tumors could lead to the simple question of
why mice are used for this in the first place. The simple
answer to this is that, until recently, the mouse was the
only species in which the genetic modification required
to model the genetic events leading to Wilms’ tumors in
patients was routinely used. However, other model
organisms could be better for developing Wilms’ tumor
models. For instance, Wilms’ tumors can be induced in
rats with high efficiency using mutagens like ENU,
especially in the inbred Nb strain (Hard 1985), but not
in mice (Vesselinovitch et al. 1977). Although these
tumors show a high incidence of nuclear b-catenin, no
mutations in Ctnnb1 or Wt1 were found (Ehrlich et al.
2010), and the patient relevance of these tumors therefore
needs to be demonstrated. In contrast, ENU-mediated
mutagenesis of outbred Sprague-Dawley rats does result
in Wilms’ tumors with mutations in Wt1 (Sharma et al.
1994). Other species in which Wilms’ tumor is found
spontaneously or can be induced are rabbits and chickens.
Mice might very well be one of the most difficult model
organisms to model Wilms’ tumors. However, the recent
advances in gene editor technologies, such as zinc finger
nucleases, TAL effector nucleases, and CRISPR/Cas9,
have opened up genomic engineering possibilities in
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these species to comparable levels that so far have only
been possible in mice (Li et al. 2013a,b; Honda et al. 2014;
Park et al. 2014; Yang et al. 2014). Maybe the time is ripe
to reconsider the best possible experimental model for
Wilms’ tumor research.
Another species that has gained much interest as
a cancer model is pigs (Flisikowska et al. 2013). Especially
for embryonal tumors like Wilms’ tumors, pigs have
potential advantages. If Wilms’ tumor development is
dependent on the right mutations being acquired at the
right developmental stage, it could be simple statistics
that the target cell population size and time during
development when these cells are present are rate-limiting
steps for Wilms’ tumor mouse models. Kidneys with the
same size as human kidneys and a gestation time of several
months could make pigs another promising new model.
Moreover, Wilms’ tumors are one of the most frequently
found spontaneous tumors found in pigs in slaughter-
houses (Cotchin 1975), and pigs can efficiently bemodified
using gene editors (Lillico et al. 2013; Li et al. 2014a).
It is unlikely that these species will ever replace mice
in the fundamental analysis of Wilms’ tumors, its genet-
ics, and its developmental background, but the availabil-
ity of new experimental species that can more efficiently
couple genetic aberrations to tumor development would
be a welcome addition to Wilms’ tumor research.
Outlook
The last few years have seen a wealth of new develop-
ments in the Wilms’ tumor field, such as the description
of the first Wilms’ tumor mouse model, the identification
of Wilms’ tumor cancer stem cells, and the recent identi-
fication of mutations in miRNA processing genes in
Wilms’ tumors. At the same time, the increased under-
standing of early kidney development, especially of the
control of the nephron progenitor cells, has provided
a detailed developmental framework in which the origins
of Wilms’ tumors can be studied and explained. Con-
versely, the role of multiple Wilms’ tumor genes in this
process illustrates the value of studying fundamental
Wilms’ tumor biology for the better understanding of
normal kidney development.
As the role of the miRNA processor pathway in Wilms’
tumor is now known to be important in tumorigenesis,
future research should focus on whether there are any
potential therapeutic avenues arising and also on the
mechanistic roles of miRNAs and the genes that process
them during normal renal development. The few studies
available on this are likely only the tip of the iceberg. As
most genetic aberrations discovered to date appear to
overlap with either the CTNNB1/WT1/WTX pathway
or the miRNA processor pathways, there may be two
distinct groups of tumors present, as indicated by targeted
sequencing of a cohort of blastemal-predominant Wilms’
tumors (Rakheja et al. 2014). However, a much larger
study is required, including otherWilms’ tumor subtypes,
to fully assess this. Furthermore, the relationship be-
tween epigenetic abnormalities (such as IGF2) and mu-
tations in miRNA processors is unknown.
The identification of miRNA processor mutations in
Wilms’ tumors emphasizes the importance of miRNAs in
normal kidney development, in particular in the nephron
progenitor cells. The Six2-Cre-mediated knockout of
Dicer1 (Nagalakshmi et al. 2011) has already demon-
strated the importance of miRNAs in these cells, and
specific miRNAs found deregulated in Wilms’ tumors
would be strong candidates to analyze for their roles in
nephron progenitors. A mouse ESC resource for the
generation of miRNA reporter and conditional knockout
alleles has been described (Prosser et al. 2011), and,
combined with Cre drivers active in many different cell
types in the developing kidney, this would provide the
experimental platform to analyze this in more detail.
Although epigenetic mechanisms play a clear role in
a subset of Wilms’ tumors in which IGF2 and H19 are
dysregulated, whether the epigenome plays an initiating
role in tumor formation is yet to be elucidated. Thus far,
mutations in two key epigenome remodelers (SMARCA4
and ARID1A) have been identified, and with further
sequencing studies, this number may increase. As WT1
and MYCN both interact with common epigenome
remodelers, the plasticity and epigenomic events detected
may indeed be a secondary event. Studies of the epigenome
within Wilms’ tumor with well-characterized genomes
will be the next step in understanding the relationship
between the two. Such data might subsequently lead to
new or better insights into the epigenetic mechanisms
underlying normal kidney development.
Acknowledgments
J.C. was funded by the University College London (UCL) Grand
Challenges Scheme, the Olivia Hodson fund, and the European
Commission FP7 project reference 270089: p-Medicine. K.P.J. is
in part supported by the National Institute for Health Research
Great Ormond Street Hospital UCL Biomedical Research Cen-
tre, Cancer Research UK (C1188/A4614), Great Ormond Street
Hospital Children’s Charity, Children with Cancer (grant refer-
ence 113), and the European Commission FP7 project reference
261474: European Network for Cancer Research in Children and
Adolescents (ENCCA). The Roslin Institute receives Institute
Strategic Programme grant funding from the Biotechnology and
Biological Sciences ResearchCouncil (BBSRC grant BB/J004316/1).
References
Aiden AP, Rivera MN, Rheinbay E, KuM, Coffman EJ, Truong TT,
Vargas SO, Lander ES, Haber DA, Bernstein BE. 2010. Wilms
tumor chromatin profiles highlight stem cell properties and
a renal developmental network. Cell Stem Cell 6: 591–602.
Anglesio MS, Evdokimova V, Melnyk N, Zhang L, Fernandez
CV, Grundy PE, Leach S, Marra MA, Brooks-Wilson AR,
Penninger J, et al. 2004. Differential expression of a novel
ankyrin containing E3 ubiquitin-protein ligase, Hace1, in
sporadic Wilms’ tumor versus normal kidney. Hum Mol
Genet 13: 2061–2074.
Astuti D, Morris MR, Cooper WN, Staals RH, Wake NC, Fews GA,
Gill H, Gentle D, Shuib S, Ricketts CJ, et al. 2012. Germline
mutations in DIS3L2 cause the Perlman syndrome of over-
growth and Wilms tumor susceptibility. Nat Genet 44:
277–284.
Wilms’ tumors and kidney development
GENES & DEVELOPMENT 477
 Cold Spring Harbor Laboratory Press on March 5, 2015 - Published by genesdev.cshlp.orgDownloaded from 
Bahubeshi A, Bal N, Rio Frio T, Hamel N, Pouchet C, Yilmaz A,
Bouron-Dal Soglio D, Williams GM, Tischkowitz M, Priest
JR, et al. 2010. Germline DICER1 mutations and familial
cystic nephroma. J Med Genet 47: 863–866.
Bardeesy N, Falkoff D, Petruzzi M-J, Nowak N, Zabel B, Adam
M, Aguiar MC, Grundy P, Shows T, Pelletier J. 1994.
Anaplastic Wilms’ tumour, a subtype displaying poor prog-
nosis, harbours p53 gene mutations. Nat Genet 7: 91–97.
Bates CM, Kharzai S, Erwin T, Rossant J, Parada LF. 2000. Role of
N-myc in the developing mouse kidney.Dev Biol 222: 317–325.
Beckwith JB, Kiviat NB, Bonadio JF. 1990. Nephrogenic rests,
nephroblastomatosis, and the pathogenesis of Wilms’ tumor.
Pediatr Pathol 10: 1–36.
Berger AH, Knudson AG, Pandolfi PP. 2011. A continuummodel
for tumour suppression. Nature 476: 163–169.
Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA,
Rose EA, Kral A, Yeger H, Lewis WH, et al. 1990. Isolation
and characterization of a zinc finger polypeptide gene at the
human chromosome 11 Wilms’ tumor locus. Cell 60: 509–520.
Chang HM, Triboulet R, Thornton JE, Gregory RI. 2013. A role
for the Perlman syndrome exonuclease Dis3l2 in the Lin28–
let-7 pathway. Nature 497: 244–248.
Charlton J, Williams RD, Sebire NJ, Popov S, Vujanic G, Chagtai T,
Alcaide-German M, Morris T, Butcher LM, Guilhamon P, et al.
2015. Comparative methylome analysis identifies new tumour
subtypes and biomarkers for transformation of nephrogenic
rests into Wilms tumour. Genome Medicine 7: 11.
Charron J, Malynn BA, Fisher P, Stewart V, Jeannotte L, Goff SP,
Robertson EJ, Alt FW. 1992. Embryonic lethality in mice
homozygous for a targeted disruption of the N-myc gene.
Genes Dev 6: 2248–2257.
Chau YY, Brownstein D, Mjoseng H, Lee WC, Buza-Vidas N,
Nerlov C, Jacobsen SE, Perry P, Berry R, Thornburn A, et al.
2011. Acute multiple organ failure in adult mice deleted for
the developmental regulator Wt1. PLoS Genet 7: e1002404.
Chilukamarri L, Hancock AL, Malik S, Zabkiewicz J, Baker JA,
Greenhough A, Dallosso AR, Huang TH, Royer-Pokora B,
Brown KW, et al. 2007. Hypomethylation and aberrant
expression of the glioma pathogenesis-related 1 gene in
Wilms tumors. Neoplasia 9: 970–978.
Clark PE, Polosukhina D, Love H, Correa H, Coffin C, Perlman
EJ, de Caestecker M, Moses HL, Zent R. 2011. b-Catenin and
K-RAS synergize to form primitive renal epithelial tumors
with features of epithelial Wilms’ tumors. Am J Pathol 179:
3045–3055.
Costantini F, Kopan R. 2010. Patterning a complex organ:
branching morphogenesis and nephron segmentation in
kidney development. Dev Cell 18: 698–712.
Cotchin E. 1975. Spontaneous tumours in young animals. Proc
R Soc Med 68: 653–655.
Cox D. 1966. Chromosome constitution of nephroblastomas.
Cancer 19: 1217–1224.
Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri
L, Tsai HH, Sarkar A, Barasch J, Vuononvirta R, Jones C,
et al. 2009. Frequent long-range epigenetic silencing of
protocadherin gene clusters on chromosome 5q31 in Wilms’
tumor. PLoS Genet 5: e1000745.
Das A, Tanigawa S, Karner CM, Xin M, Lum L, Chen C, Olson
EN, Perantoni AO, Carroll TJ. 2013. Stromal–epithelial
crosstalk regulates kidney progenitor cell differentiation.
Nat Cell Biol 15: 1035–1044.
Davies JA, Ladomery M, Hohenstein P, Michael L, Shafe A,
Spraggon L, Hastie N. 2004. Development of an siRNA-based
method for repressing specific genes in renal organ culture and
its use to show that the Wt1 tumour suppressor is required for
nephron differentiation. Hum Mol Genet 13: 235–246.
Dekel B, Metsuyanim S, Schmidt-Ott KM, Fridman E, Jacob-
Hirsch J, Simon A, Pinthus J, Mor Y, Barasch J, Amariglio N,
et al. 2006. Multiple imprinted and stemness genes provide
a link between normal and tumor progenitor cells of the
developing human kidney. Cancer Res 66: 6040–6049.
Ding L, Paszkowski-Rogacz M, Nitzsche A, Slabicki MM,
Heninger AK, de Vries I, Kittler R, Junqueira M, Shevchenko
A, Schulz H, et al. 2009. A genome-scale RNAi screen for
Oct4 modulators defines a role of the Paf1 complex for
embryonic stem cell identity. Cell Stem Cell 4: 403–415.
Drake KM, Ruteshouser EC, Natrajan R, Harbor P, Wegert J,
Gessler M, Pritchard-Jones K, Grundy P, Dome J, Huff V, et al.
2009. Loss of heterozygosity at 2q37 in sporadic Wilms’ tumor:
putative role for miR-562. Clin Cancer Res 15: 5985–5992.
Ehrlich M, Hopkins NE, Jiang G, Dome JS, Yu MC, Woods CB,
Tomlinson GE, Chintagumpala M, Champagne M, Dillerg L,
et al. 2003. Satellite DNA hypomethylation in karyotyped
Wilms tumors. Cancer Genet Cytogenet 141: 97–105.
Ehrlich D, Bruder E, Thome MA, Gutt CN, von Knebel
Doeberitz M, Niggli F, Perantoni AO, Koesters R. 2010.
Nuclear accumulation of b-catenin protein indicates activa-
tion of wnt signaling in chemically induced rat nephroblas-
tomas. Pediatr Dev Pathol 13: 1–8.
El-Dahr S, Hilliard S, Aboudehen K, Saifudeen Z. 2014. The
MDM2–p53 pathway: multiple roles in kidney development.
Pediatr Nephrol 29: 621–627.
Essafi A, Webb A, Berry RL, Slight J, Burn SF, Spraggon L,
Velecela V, Martinez-Estrada OM, Wiltshire JH, Roberts SG,
et al. 2011. A Wt1-controlled chromatin switching mecha-
nism underpins tissue-specific Wnt4 activation and repres-
sion. Dev Cell 21: 559–574.
Flisikowska T, Kind A, Schnieke A. 2013. The new pig on the
block: modelling cancer in pigs. Transgenic Res 22: 673–680.
Foulkes WD, Bahubeshi A, Hamel N, Pasini B, Asioli S, Baynam
G, Choong CS, Charles A, Frieder RP, Dishop MK, et al.
2011. Extending the phenotypes associated with DICER1
mutations. Hum Mutat 32: 1381–1384.
Francke U, Holmes LB, Atkins L, Riccardi VM. 1979. Aniridia-
Wilms’ tumor association: evidence for specific deletion of
11p13. Cytogenet Cell Genet 24: 185–192.
Frese KK, Tuveson DA. 2007. Maximizing mouse cancer
models. Nat Rev Cancer 7: 645–658.
Fukuzawa R, Heathcott RW,More HE, Reeve AE. 2007. Sequential
WT1 and CTNNB1 mutations and alterations of b-catenin
localisation in intralobar nephrogenic rests and associated
Wilms tumours: two case studies. J Clin Pathol 60: 1013–1016.
Fukuzawa R, Holman SK, Chow CW, Savarirayan R, Reeve AE,
Robertson SP. 2010. WTX mutations can occur both early
and late in the pathogenesis of Wilms tumour. J Med Genet
47: 791–794.
Gadd S, Huff V, Huang CC, Ruteshouser EC, Dome JS, Grundy
PE, Breslow N, Jennings L, Green DM, Beckwith JB, et al.
2012. Clinically relevant subsets identified by gene expression
patterns support a revised ontogenic model of Wilms tumor:
a children’s oncology group study. Neoplasia 14: 742–756.
Gao F, Maiti S, Sun G, Ordonez NG, Udtha M, Deng JM,
Behringer RR, Huff V. 2004. The Wt1+/R394W mouse dis-
plays glomerulosclerosis and early-onset renal failure char-
acteristic of human Denys-Drash syndrome. Mol Cell Biol
24: 9899–9910.
Gebeshuber CA, Kornauth C, Dong L, Sierig R, Seibler J, Reiss
M, Tauber S, Bilban M, Wang S, Kain R, et al. 2013. Focal
segmental glomerulosclerosis is induced by microRNA-193a
and its downregulation of WT1. Nat Med 19: 481–487.
Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH,
Bruns GA. 1990. Homozygous deletion in Wilms tumours of
Hohenstein et al.
478 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on March 5, 2015 - Published by genesdev.cshlp.orgDownloaded from 
a zinc-finger gene identified by chromosome jumping. Nature
343: 774–778.
Grill C, Sunitsch S, Hatz M, Hauser-Kronberger C, Leuschner I,
Hoefler G, Guertl B. 2011. Activation of b-catenin is a late event
in the pathogenesis of nephroblastomas and rarely correlated
with genetic changes of the APC gene. Pathology 43: 702–706.
Grundy P, Coppes MJ, Haber D. 1995. Molecular genetics of
Wilms tumor. Hematol Oncol Clin North Am 9: 1201–1215.
Guertl B, Leuschner I, Guelly C, Ebner B, Kronberger C, Hoefler G.
2010. Is predisposition for nephroblastoma linked to polymor-
phisms of the WTX gene?. Pathol Oncol Res 16: 189–191.
Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D,
Hammes A, Hastie ND, Schedl A. 2002. WT1 is a key
regulator of podocyte function: reduced expression levels
cause crescentic glomerulonephritis and mesangial sclerosis.
Hum Mol Genet 11: 651–659.
Hammes A, Guo JK, Lutsch G, Leheste JR, Landrock D, Ziegler
U, Gubler MC, Schedl A. 2001. Two splice variants of the
Wilms’ tumor 1 gene have distinct functions during sex
determination and nephron formation. Cell 106: 319–329.
Hanks S, Perdeaux ER, Seal S, Ruark E, Mahamdallie SS, Murray
A, Ramsay E, Del Vecchio Duarte S, Zachariou A, de Souza
B, et al. 2014. Germline mutations in the PAF1 complex gene
CTR9 predispose to Wilms tumour. Nat Commun 5: 4398.
Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL,
Matta H, Miyajima K, Timmons CF, Tomlinson GE,
Mastrangelo D, et al. 2002. Deregulation of Caspase 8
and 10 expression in pediatric tumors and cell lines.
Cancer Res 62: 5897–5901.
Harari-Steinberg O, Metsuyanim S, Omer D, Gnatek Y, Gershon
R, Pri-Chen S, Ozdemir DD, Lerenthal Y, Noiman T, Ben-Hur
H, et al. 2013. Identification of human nephron progenitors
capable of generation of kidney structures and functional
repair of chronic renal disease. EMBOMol Med 5: 1556–1568.
Hard GC. 1985. Differential renal tumor response to N-ethyl-
nitrosourea and dimethylnitrosamine in the Nb rat: basis for
a new rodent model of nephroblastoma. Carcinogenesis 6:
1551–1558.
Haruta M, Matsumoto Y, Izumi H, Watanabe N, Fukuzawa M,
Matsuura S, Kaneko Y. 2008. Combined BubR1 protein
down-regulation and RASSF1A hypermethylation in Wilms
tumors with diverse cytogenetic changes. Mol Carcinog 47:
660–666.
Heo I, Joo C, Kim YK, Ha M, Yoon MJ, Cho J, Yeom KH, Han J,
Kim VN. 2009. TUT4 in concert with Lin28 suppresses
microRNA biogenesis through pre-microRNA uridylation.
Cell 138: 696–708.
Holm TM, Jackson-Grusby L, Brambrink T, Yamada Y, Rideout
WM 3rd, Jaenisch R. 2005. Global loss of imprinting leads
to widespread tumorigenesis in adult mice. Cancer Cell 8:
275–285.
Honda A, Hirose M, Sankai T, Yasmin L, Yuzawa K, Honsho K,
Izu H, Iguchi A, Ikawa M, Ogura A 2014. Single-step
generation of rabbits carrying a targeted allele of the tyros-
inase gene using CRISPR/Cas9. Exp Anim doi: 1538/
expanim.14-0034.
Hu Q, Gao F, TianW, Ruteshouser EC, Wang Y, Lazar A, Stewart J,
Strong LC, Behringer RR, Huff V. 2011. Wt1 ablation and Igf2
upregulation in mice result in Wilms tumors with elevated
ERK1/2 phosphorylation. J Clin Invest 121: 174–183.
Hubertus J, Lacher M, Rottenkolber M, Muller-Hocker J, Berger
M, Stehr M, von Schweinitz D, Kappler R. 2011. Altered
expression of imprinted genes in Wilms tumors. Oncol Rep
25: 817–823.
Hubertus J, Zitzmann F, Trippel F, Muller-Hocker J, Stehr M,
von Schweinitz D, Kappler R. 2013. Selective methylation of
CpGs at regulatory binding sites controls NNAT expression
in Wilms tumors. PLoS ONE 8: e67605.
Huff V. 2011. Wilms’ tumours: about tumour suppressor genes, an
oncogene and a chameleon gene. Nat Rev Cancer 11: 111–121.
Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy
C, Chen Y, Rao MK. 2010. MicroRNA-185 suppresses tumor
growth and progression by targeting the Six1 oncogene in
human cancers. Oncogene 29: 4971–4979.
Jaehning JA. 2010. The Paf1 complex: platform or player in RNA
polymerase II transcription?. Biochim Biophys Acta 1799:
379–388.
Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R,
Pearl E, Thaller C, Hing AV, Porteous ME, Garcia-Minaur S,
et al. 2009. Germline mutations in WTX cause a sclerosing
skeletal dysplasia but do not predispose to tumorigenesis.
Nat Genet 41: 95–100.
Kaneko Y, Egues MC, Rowley JD. 1981. Interstitial deletion of
short arm of chromosome 11 limited to Wilms’ tumor cells
in a patient without aniridia. Cancer Res 41: 4577–4578.
Karner CM, Das A, Ma Z, Self M, Chen C, Lum L, Oliver G,
Carroll TJ. 2011. Canonical Wnt9b signaling balances pro-
genitor cell expansion and differentiation during kidney
development. Development 138: 1247–1257.
Kim MS, Yoon SK, Bollig F, Kitagaki J, Hur W, Whye NJ, Wu YP,
Rivera MN, Park JY, Kim HS, et al. 2010. A novel Wilms
tumor 1 (WT1) target gene negatively regulates the WNT
signaling pathway. J Biol Chem 285: 14585–14593.
Kim WJ, Rivera MN, Coffman EJ, Haber DA. 2012. The WTX
tumor suppressor enhances p53 acetylation by CBP/p300.
Mol Cell 45: 587–597.
Kispert A, Vainio S, McMahon AP. 1998. Wnt-4 is a mesenchy-
mal signal for epithelial transformation of metanephric
mesenchyme in the developing kidney. Development 125:
4225–4234.
Knudson AG Jr, Strong LC. 1972. Mutation and cancer: a model for
Wilms’ tumor of the kidney. J Natl Cancer Inst 48: 313–324.
Kobayashi A, Valerius MT, Mugford JW, Carroll TJ, Self M,
Oliver G, McMahon AP. 2008. Six2 defines and regulates
a multipotent self-renewing nephron progenitor population
throughout mammalian kidney development. Cell Stem
Cell 3: 169–181.
Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V,
Niggli F, Briner J, von Knebel Doeberitz M. 1999. Mutational
activation of the b-catenin proto-oncogene is a common
event in the development of Wilms’ tumors. Cancer Res 59:
3880–3882.
Koesters R, Niggli F, von Knebel Doeberitz M, Stallmach T.
2003. Nuclear accumulation of b-catenin protein in Wilms’
tumours. J Pathol 199: 68–76.
Koller K, Das S, Leuschner I, Korbelius M, Hoefler G, Guertl B.
2013. Identification of the transcription factor HOXB4 as
a novel target of miR-23a. Genes Chromosomes Cancer 52:
709–715.
Kort EJ, Farber L, Tretiakova M, Petillo D, Furge KA, Yang XJ,
Cornelius A, Teh BT. 2008. The E2F3–Oncomir-1 axis is
activated in Wilms’ tumor. Cancer Res 68: 4034–4038.
Koufos A, Grundy P, Morgan K, Aleck KA, Hadro T, Lampkin
BC, Kalbakji A, Cavenee WK. 1989. Familial Wiedemann-
Beckwith syndrome and a second Wilms tumor locus both
map to 11p15.5. Am J Hum Genet 44: 711–719.
Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J,
Housman D, Jaenisch R. 1993. WT-1 is required for early
kidney development. Cell 74: 679–691.
Kusafuka T, Miao J, Kuroda S, Udatsu Y, Yoneda A. 2002. Codon
45 of the b-catenin gene, a specific mutational target site of
Wilms’ tumor. Int J Mol Med 10: 395–399.
Wilms’ tumors and kidney development
GENES & DEVELOPMENT 479
 Cold Spring Harbor Laboratory Press on March 5, 2015 - Published by genesdev.cshlp.orgDownloaded from 
Laurenti E, Wilson A, Trumpp A. 2009. Myc’s other life: stem
cells and beyond. Curr Opin Cell Biol 21: 844–854.
Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman
SM. 1995. Disruption of imprinting caused by deletion of the
H19 gene region in mice. Nature 375: 34–39.
Lemoine NR, Hughes CM, Cowell JK. 1992. Aberrant expres-
sion of the tumour suppressor gene p53 is very frequent in
Wilms’ tumours. J Pathol 168: 237–242.
Li D, Qiu Z, Shao Y, Chen Y, Guan Y, Liu M, Li Y, Gao N, Wang L,
Lu X, et al. 2013a. Heritable gene targeting in the mouse and rat
using a CRISPR–Cas system. Nat Biotechnol 31: 681–683.
Li W, Teng F, Li T, Zhou Q. 2013b. Simultaneous generation and
germline transmission of multiple gene mutations in rat
using CRISPR–Cas systems. Nat Biotechnol 31: 684–686.
Li F, Cowley DO, Banner D, Holle E, Zhang L, Su L. 2014a.
Efficient genetic manipulation of the NOD–Rag1/IL2RgC-
null mouse by combining in vitro fertilization and CRISPR/
Cas9 technology. Sci Rep 4: 5290.
Li W, Hartwig S, Rosenblum ND. 2014b. Developmental origins
and functions of stromal cells in the normal and diseased
mammalian kidney. Dev Dyn 243: 853–863.
Lillico SG, Proudfoot C, Carlson DF, Stverakova D, Neil C,
Blain C, King TJ, Ritchie WA, Tan W, Mileham AJ, et al.
2013. Live pigs produced from genome edited zygotes. Sci
Rep 3: 2847.
Ludgate JL, Le Mee G, Fukuzawa R, Rodger EJ, Weeks RJ, Reeve
AE, Morison IM. 2013. Global demethylation in loss of
imprinting subtype of Wilms tumor. Genes Chromosomes
Cancer 52: 174–184.
Maiti S, Alam R, Amos CI, Huff V. 2000. Frequent association of
b-catenin and WT1 mutations in Wilms tumors. Cancer Res
60: 6288–6292.
Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert
C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, et al.
2007. Wilms tumor suppressor WTX negatively regulates
WNT/b-catenin signaling. Science 316: 1043–1046.
Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ,
Vujanic G, Perlman E, Anderson JR, Grundy P, Dome JS,
et al. 2014. TP53 mutational status is a potential marker for
risk stratification in Wilms tumour with diffuse anaplasia.
PLoS ONE 9: e109924.
Menke AL, IJpenberg A, Fleming S, Ross A, Medine CN, Patek
CE, Spraggon L, Hughes J, Clarke AR, Hastie ND. 2003. The
wt1-heterozygous mouse; a model to study the development
of glomerular sclerosis. J Pathol 200: 667–674.
Metsuyanim S, Pode-Shakked N, Schmidt-Ott KM, Keshet G,
Rechavi G, Blumental D, Dekel B. 2008. Accumulation of
malignant renal stem cells is associated with epigenetic
changes in normal renal progenitor genes. Stem Cells 26:
1808–1817.
Metsuyanim S, Harari-Steinberg O, Buzhor E, Omer D, Pode-
Shakked N, Ben-Hur H, Halperin R, Schneider D, Dekel B.
2009. Expression of stem cell markers in the human fetal
kidney. PLoS ONE 4: e6709.
Miller-Hodges E, Hohenstein P. 2012. WT1 in disease: shifting
the epithelial–mesenchymal balance. J Pathol 226: 229–240.
Miyagawa K, Kent J, Moore A, Charlieu JP, Little MH, Williamson
KA, Kelsey A, Brown KW, Hassam S, Briner J, et al. 1998. Loss
of WT1 function leads to ectopic myogenesis in Wilms’
tumour. Nat Genet 18: 15–17.
Moisan A, Rivera MN, Lotinun S, Akhavanfard S, Coffman EJ,
Cook EB, Stoykova S, Mukherjee S, Schoonmaker JA, Burger A,
et al. 2011. The WTX tumor suppressor regulates mesenchy-
mal progenitor cell fate specification. Dev Cell 20: 583–596.
Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees
RD, Cooper WN, Lee J, Gentle D, Macdonald F, et al. 2003.
Multigene methylation analysis of Wilms’ tumour and adult
renal cell carcinoma. Oncogene 22: 6794–6801.
Mugrauer G, Alt FW, Ekblom P. 1988. N-myc proto-oncogene
expression during organogenesis in the developing mouse as
revealed by in situ hybridization. J Cell Biol 107: 1325–1335.
Murphy AJ, Pierce J, de Caestecker C, Libes J, Neblett D, de
Caestecker M, Perantoni AO, Tanigawa S, Anderson JR, Dome
JS, et al. 2014. Aberrant activation, nuclear localization, and
phosphorylation of Yes-associated protein-1 in the embryonic
kidney and Wilms tumor. Pediatr Blood Cancer 61: 198–205.
Nagalakshmi VK, Ren Q, Pugh MM, Valerius MT, McMahon
AP, Yu J. 2011. Dicer regulates the development of nephro-
genic and ureteric compartments in the mammalian kidney.
Kidney Int 79: 317–330.
Nisen PD, Zimmerman KA, Cotter SV, Gilbert F, Alt FW. 1986.
Enhanced expression of the N-myc gene in Wilms’ tumors.
Cancer Res 46: 6217–6222.
Nishiyama R, Qi L, Lacey M, Ehrlich M. 2005. Both hypometh-
ylation and hypermethylation in a 0.2-kb region of a DNA
repeat in cancer. Mol Cancer Res 3: 617–626.
Norris MD, Brian MJ, Vowels MR, Stewart BW. 1988. N-myc
amplification in Wilms’ tumor. Cancer Genet Cytogenet 30:
187–189.
Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA,
Smith PJ, Reeve AE. 1993. Relaxation of insulin-like growth
factor II gene imprinting implicated in Wilms’ tumour.
Nature 362: 749–751.
Ohlsson R, Cui H, He L, Pfeifer S, Malmikumpu H, Jiang S,
Feinberg AP, Hedborg F. 1999. Mosaic allelic insulin-like
growth factor 2 expression patterns reveal a link between
Wilms’ tumorigenesis and epigenetic heterogeneity. Cancer
Res 59: 3889–3892.
Ohnishi K, Semi K, Yamamoto T, Shimizu M, Tanaka A,
Mitsunaga K, Okita K, Osafune K, Arioka Y, Maeda T,
et al. 2014. Premature termination of reprogramming in vivo
leads to cancer development through altered epigenetic
regulation. Cell 156: 663–677.
Ohshima J, Haruta M, Fujiwara Y, Watanabe N, Arai Y, Ariga T,
Okita H, Koshinaga T, Oue T, Hinotsu S, et al. 2012.
Methylation of the RASSF1A promoter is predictive of poor
outcome among patients with Wilms tumor. Pediatr Blood
Cancer 59: 499–505.
Okutsu T, Kuroiwa Y, Kagitani F, Kai M, Aisaka K, Tsutsumi
O, Kaneko Y, Yokomori K, Surani MA, Kohda T, et al.
2000. Expression and imprinting status of human PEG8/
IGF2AS, a paternally expressed antisense transcript from the
IGF2 locus, in Wilms’ tumors. J Biochem 127: 475–483.
Ozdemir DD, Hohenstein P. 2014. Wt1 in the kidney—a tale in
mouse models. Pediatr Nephrol 29: 687–693.
Park S, Bernard A, Bove KE, Sens DA, Hazen-Martin DJ, Garvin
AJ, Haber DA. 1993. Inactivation of WT1 in nephrogenic
rests, genetic precursors to Wilms’ tumour. Nat Genet 5:
363–367.
Park JS, Ma W, O’Brien LL, Chung E, Guo JJ, Cheng JG, Valerius
MT, McMahon JA, Wong WH, McMahon AP. 2012. Six2 and
Wnt regulate self-renewal and commitment of nephron pro-
genitors through shared gene regulatory networks. Dev Cell
23: 637–651.
Park TS, Lee HJ, Kim KH, Kim JS, Han JY. 2014. Targeted gene
knockout in chickens mediated by TALENs. Proc Natl Acad
Sci 111: 12716–12721.
Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC,
Striegel JE, Houghton DC, Junien C, Habib R, Fouser L, et al.
1991. Germline mutations in the Wilms’ tumor suppressor
gene are associated with abnormal urogenital development
in Denys-Drash syndrome. Cell 67: 437–447.
Hohenstein et al.
480 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on March 5, 2015 - Published by genesdev.cshlp.orgDownloaded from 
Perotti D, Hohenstein P, Bongarzone I, Maschietto M, Weeks M,
Radice P, Pritchard-Jones K. 2013. IsWilms tumor a candidate
neoplasia for treatment with WNT/b-catenin pathway
modulators?—A report from the renal tumors biology-driven
drug development workshop. Mol Cancer Ther 12: 2619–
2627.
Pode-Shakked N, Dekel B. 2011. Wilms tumor–a renal stem cell
malignancy? Pediatr Nephrol 26: 1535–1543.
Pode-Shakked N, Shukrun R, Mark-Danieli M, Tsvetkov P,
Bahar S, Pri-Chen S, Goldstein RS, Rom-Gross E, Mor Y,
Fridman E, et al. 2013. The isolation and characterization of
renal cancer initiating cells from human Wilms’ tumour xeno-
grafts unveils new therapeutic targets. EMBOMolMed 5: 18–37.
Preger-Ben Noon E, Barak H, Guttmann-Raviv N, Reshef R.
2009. Interplay between activin and Hox genes determines
the formation of the kidney morphogenetic field. Develop-
ment 136: 1995–2004.
Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous
D, Gosden C, Bard J, Buckler A, Pelletier J, Housman D, et al.
1990. The candidate Wilms’ tumour gene is involved in
genitourinary development. Nature 346: 194–197.
Prosser HM, Koike-Yusa H, Cooper JD, Law FC, Bradley A. 2011.
A resource of vectors and ES cells for targeted deletion of
microRNAs in mice. Nat Biotechnol 29: 840–845.
Rakheja D, Chen KS, Liu Y, Shukla AA, Schmid V, Chang TC,
Khokhar S, Wickiser JE, Karandikar NJ, Malter JS, et al. 2014.
Somatic mutations in DROSHA and DICER1 impair micro-
RNA biogenesis through distinct mechanisms in Wilms
tumours. Nat Commun 2: 4802.
Ripoche MA, Kress C, Poirier F, Dandolo L. 1997. Deletion of
the H19 transcription unit reveals the existence of a puta-
tive imprinting control element. Genes Dev 11: 1596–
1604.
Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han
M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, et al. 2007.
An X chromosome gene, WTX, is commonly inactivated in
Wilms tumor. Science 315: 642–645.
Rivera MN, Kim WJ, Wells J, Stone A, Burger A, Coffman EJ,
Zhang J, Haber DA. 2009. The tumor suppressor WTX
shuttles to the nucleus and modulates WT1 activity. Proc
Natl Acad Sci 106: 8338–8343.
Ruteshouser EC, Robinson SM, Huff V. 2008. Wilms tumor
genetics: mutations in WT1, WTX, and CTNNB1 account
for only about one-third of tumors. Genes Chromosomes
Cancer 47: 461–470.
Saifudeen Z, Dipp S, Stefkova J, Yao X, Lookabaugh S, El-Dahr
SS. 2009. p53 regulates metanephric development. J Am Soc
Nephrol 20: 2328–2337.
Schell C, Wanner N, Huber TB. 2014. Glomerular develop-
ment—shaping the multi-cellular filtration unit. Semin Cell
Dev Biol 36: 39–49.
Schneid H, Vazquez MP, Seurin D, le Bouc Y. 1991. Loss of
heterozygosity in non-tumoral tissue in two children with
Beckwith-Wiedemann syndrome. Growth Regul 1: 168–
170.
Schroeder WT, Chao LY, Dao DD, Strong LC, Pathak S, Riccardi
V, Lewis WH, Saunders GF. 1987. Nonrandom loss of
maternal chromosome 11 alleles in Wilms tumors. Am J
Hum Genet 40: 413–420.
Schumacher V, Schneider S, Figge A, Wildhardt G, Harms D,
Schmidt D, Weirich A, Ludwig R, Royer-Pokora B. 1997.
Correlation of germ-line mutations and two-hit inactivation
of the WT1 gene with Wilms tumors of stromal-predominant
histology. Proc Natl Acad Sci 94: 3972–3977.
Schumacher V, Schuhen S, Sonner S, Weirich A, Leuschner I,
Harms D, Licht J, Roberts S, Royer-Pokora B. 2003. Two
molecular subgroups of Wilms’ tumors with or without WT1
mutations. Clin Cancer Res 9: 2005–2014.
Scott J, Cowell J, Robertson ME, Priestley LM, Wadey R,
Hopkins B, Pritchard J, Bell GI, Rall LB, Graham CF, et al.
1985. Insulin-like growth factor-II gene expression in Wilms’
tumour and embryonic tissues. Nature 317: 260–262.
Self M, Lagutin OV, Bowling B, Hendrix J, Cai Y, Dressler GR,
Oliver G. 2006. Six2 is required for suppression of nephro-
genesis and progenitor renewal in the developing kidney.
EMBO J 25: 5214–5228.
Senanayake U, Das S, Vesely P, Alzoughbi W, Frohlich LF,
Chowdhury P, Leuschner I, Hoefler G, Guertl B. 2012.
miR-192, miR-194, miR-215, miR-200c and miR-141 are
downregulated and their common target ACVR2B is strongly
expressed in renal childhood neoplasms. Carcinogenesis 33:
1014–1021.
Sharma PM, Bowman M, Yu BF, Sukumar S. 1994. A rodent
model for Wilms tumors: embryonal kidney neoplasms
induced by N-nitroso-N9-methylurea. Proc Natl Acad Sci
91: 9931–9935.
Shigematsu H, Suzuki M, Takahashi T, Miyajima K, Toyooka S,
Shivapurkar N, Tomlinson GE, Mastrangelo D, Pass HI,
Brambilla E, et al. 2005. Aberrant methylation of HIN-1
(high in normal-1) is a frequent event in many human
malignancies. Int J Cancer 113: 600–604.
Shukrun R, Pode-Shakked N, Pleniceanu O, Omer D, Vax E,
Peer E, Pri-Chen S, Jacob J, Hu Q, Harari-Steinberg O, et al.
2014. Wilms’ tumor blastemal stem cells dedifferentiate to
propagate the tumor bulk. Stem Cell Reports 3: 24–33.
Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks
S, Barfoot R, Burke A, Chisholm J, Hewitt M, et al. 2011.
DICER1 syndrome: clarifying the diagnosis, clinical features
and management implications of a pleiotropic tumour pre-
disposition syndrome. J Med Genet 48: 273–278.
Slater RM, de Kraker J. 1982. Chromosome number 11 and
Wilms’ tumor. Cancer Genet Cytogenet 5: 237–245.
Stark K, Vainio S, Vassileva G, McMahon AP. 1994. Epithelial
transformation of metanephric mesenchyme in the develop-
ing kidney regulated by Wnt-4. Nature 372: 679–683.
Stricker SH, Feber A, Engstrom PG, Caren H, Kurian KM,
Takashima Y, Watts C, Way M, Dirks P, Bertone P, et al.
2013. Widespread resetting of DNA methylation in glioblas-
toma-initiating cells suppresses malignant cellular behavior
in a lineage-dependent manner. Genes Dev 27: 654–669.
Sun FL, Dean WL, Kelsey G, Allen ND, Reik W. 1997. Trans-
activation of Igf2 in a mouse model of Beckwith-Wiedemann
syndrome. Nature 389: 809–815.
Szemes M, Dallosso AR, Melegh Z, Curry T, Li Y, Rivers C, Uney
J, Magdefrau AS, Schwiderski K, Park JH, et al. 2013. Control
of epigenetic states by WT1 via regulation of de novo DNA
methyltransferase 3A. Hum Mol Genet 22: 74–83.
Thornton JE, Chang HM, Piskounova E, Gregory RI. 2012.
Lin28-mediated control of let-7 microRNA expression by
alternative TUTases Zcchc11 (TUT4) and Zcchc6 (TUT7).
RNA 18: 1875–1885.
TimpW, Feinberg AP. 2013. Cancer as a dysregulated epigenome
allowing cellular growth advantage at the expense of the
host. Nat Rev Cancer 13: 497–510.
Torrezan GT, Ferreira EN, Nakahata AM, Barros BD, Castro
MT, Correa BR, Krepischi AC, Olivieri EH, Cunha IW, Tabori
U, et al. 2014. Recurrent somatic mutation in DROSHA
induces microRNA profile changes in Wilms tumour. Nat
Commun 5: 4039.
Udtha M, Lee SJ, Alam R, Coombes K, Huff V. 2003. Upregu-
lation of c-MYC in WT1-mutant tumors: assessment of WT1
putative transcriptional targets using cDNA microarray
Wilms’ tumors and kidney development
GENES & DEVELOPMENT 481
 Cold Spring Harbor Laboratory Press on March 5, 2015 - Published by genesdev.cshlp.orgDownloaded from 
expression profiling of genetically defined Wilms’ tumors.
Oncogene 22: 3821–3826.
Urbach A, Yermalovich A, Zhang J, Spina CS, Zhu H, Perez-
Atayde AR, Shukrun R, Charlton J, Sebire N, Mifsud W, et al.
2014. Lin28 sustains early renal progenitors and induces
Wilms tumor. Genes Dev 28: 971–982.
Vesselinovitch SD, Koka M, Rao KV, Mihailovich N, Rice JM.
1977. Prenatal multicarcinogenesis by ethylnitrosourea in
mice. Cancer Res 37: 1822–1828.
Visvader JE. 2011. Cells of origin in cancer. Nature 469:
314–322.
Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C,
Wadey RB, Morton D, Schofield PN, Reik W, Latif F, et al.
2002. Frequent RASSF1A tumour suppressor gene promoter
methylation in Wilms’ tumour and colorectal cancer.
Oncogene 21: 7277–7282.
Walz AL, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil
JM, Meerzaman D, Chen Q-R, Hsu CH, Yan C, et al. 2015.
Recurrent DGCR8, DROSHA, and SIX homeodomainmutations
in favorable histology Wilms tumors. Cancer Cell 27: 286–297.
Watson JA, Bryan K, Williams R, Popov S, Vujanic G, Coulomb
A, Boccon-Gibod L, Graf N, Pritchard-Jones K, O’Sullivan M.
2013. miRNA profiles as a predictor of chemoresponsiveness
in Wilms’ tumor blastema. PLoS ONE 8: e53417.
Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N,
Gessler M. 2009. WTX inactivation is a frequent, but late
event in Wilms tumors without apparent clinical impact.
Genes Chromosomes Cancer 48: 1102–1111.
Wegert J, Ishaque N, Vardapour R, Georg C, Gu Z, Bieg M,
Ziegler B, Bausenwein S, Nourkami N, Ludwig N, et al. 2015.
Mutations in the SIX1/2 pathway and the DROSHA/DGCR8
miRNA microprocessor complex underlie high-risk blaste-
mal type Wilms tumors. Cancer Cell 27: 298–311.
Wilkins RJ. 1988. Genomic imprinting and carcinogenesis.
Lancet 1: 329–331.
Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire
N, Gessler M, Wegert J, Graf N, Leuschner I, et al. 2010.
Subtype-specific FBXW7 mutation and MYCN copy number
gain in Wilms’ tumor. Clin Cancer Res 16: 2036–2045.
Williams RD, Chagtai T, Alcaide-German M, Apps J, Wegert J,
Popov S, Vujanic G, Van Tinteren H, van den Heuvel-Eibrink
MM, Kool M, et al. 2015. Multiple mechanisms of MYCN
dysregulation in Wilms tumour. Oncotarget (in press).
Wirths O, Waha A, Weggen S, Schirmacher P, Kuhne T, Goodyer
CG, Albrecht S, Von Schweinitz D, Pietsch T. 2003. Over-
expression of human Dickkopf-1, an antagonist of wingless/
WNT signaling, in human hepatoblastomas and Wilms’
tumors. Lab Invest 83: 429–434.
Wu MK, Sabbaghian N, Xu B, Addidou-Kalucki S, Bernard C,
Zou D, Reeve AE, Eccles MR, Cole C, Choong CS, et al.
2013. Biallelic DICER1 mutations occur in Wilms tumours. J
Pathol 230: 154–164.
Xin Z, Soejima H, Higashimoto K, Yatsuki H, Zhu X, Satoh Y,
Masaki Z, Kaneko Y, Jinno Y, Fukuzawa R, et al. 2000. A
novel imprinted gene, KCNQ1DN, within the WT2 critical
region of human chromosome 11p15.5 and its reduced
expression in Wilms’ tumors. J Biochem 128: 847–853.
Xu PX. 2013. The EYA–SO/SIX complex in development and
disease. Pediatr Nephrol 28: 843–854.
Xu PX, Zheng WM, Huang L, Maire P, Laclef C, Silvius D. 2003.
Six1 is required for the early organogenesis of mammalian
kidney. Development 130: 3085–3094.
Xu B, Zeng D-q, Wu Y, Zheng R, Gu L, Lin X, Hua X, Jin G-H.
2011. Tumor suppressor menin represses paired box gene 2
expression via Wilms tumor suppressor protein-polycomb
group complex. J Biol Chem 286: 13937–13944.
Xu J, Wong EM, Cheng C, Li J, Sharkar MTK, Xu CY, Chen B,
Sun J, Jing D, Xu PX. 2014. Eya1 interacts with Six2 and Myc
to regulate expansion of the nephron progenitor pool during
nephrogenesis. Dev Cell 31: 434–447.
Yang D, Xu J, Zhu T, Fan J, Lai L, Zhang J, Chen YE. 2014.
Effective gene targeting in rabbits using RNA-guided Cas9
nucleases. J Mol Cell Biol 6: 97–99.
Zhang X, Xing G, Saunders GF. 1999. Proto-oncogene N-myc
promoter is down regulated by the Wilms’ tumor suppressor
gene WT1. Anticancer Res 19: 1641–1648.
Zitzmann F, Mayr D, Berger M, Stehr M, von Schweinitz D,
Kappler R, Hubertus J. 2014. Frequent hypermethylation of
a CTCF binding site influences Wilms tumor 1 expression in
Wilms tumors. Oncol Rep 31: 1871–1876.
Hohenstein et al.
482 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on March 5, 2015 - Published by genesdev.cshlp.orgDownloaded from 
 10.1101/gad.256396.114Access the most recent version at doi:
 2015 29: 467-482 Genes Dev.
  
Peter Hohenstein, Kathy Pritchard-Jones and Jocelyn Charlton
  
The yin and yang of kidney development and Wilms' tumors
  
References
  
 http://genesdev.cshlp.org/content/29/5/467.full.html#ref-list-1
This article cites 159 articles, 51 of which can be accessed free at:
  
License
Commons 
Creative
.http://creativecommons.org/licenses/by-nc/4.0/at 
Creative Commons License (Attribution-NonCommercial 4.0 International), as described 
). After six months, it is available under ahttp://genesdev.cshlp.org/site/misc/terms.xhtml
six months after the full-issue publication date (see 
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first
Service
Email Alerting
 click here.right corner of the article or
Receive free email alerts when new articles cite this article - sign up in the box at the top
Collections
Topic
  
 (132 articles)  Development
 (141 articles)  Cancer and Disease Models
  
Articles on similar topics can be found in the following collections 
 http://genesdev.cshlp.org/subscriptions
go to: Genes & Development To subscribe to 
© 2015 Hohenstein et al.; Published by Cold Spring Harbor Laboratory Press
 Cold Spring Harbor Laboratory Press on March 5, 2015 - Published by genesdev.cshlp.orgDownloaded from 
